Patients relapsing early after FC or FCR have a poor outcome. OS from the time point of second-line treatment for patients initially treated in the CLL8 trial (FC vs. FCR) according to remission duration after first-line treatment. Patients with short remissions (<24 months) have very poor outcomes, suggesting that these patients should be considered for investigational treatment and allo-SCT.